NORQUEST FE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NORQUEST FE (NORQUEST FE).
NORQUEST FE is a combination oral contraceptive containing ethinyl estradiol and norethindrone. Ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation. Norethindrone induces progestational changes in the endometrium, increasing cervical mucus viscosity, and also inhibits ovulation.
| Metabolism | Ethinyl estradiol is metabolized via CYP3A4, with phase II conjugation (glucuronidation and sulfation). Norethindrone is metabolized via reduction and conjugation, primarily as sulfate and glucuronide conjugates. |
| Excretion | Renal: 80% (50% unchanged, 30% as metabolites); Fecal: 19%; Biliary: <1% |
| Half-life | Terminal half-life: 6-8 hours. Clinical context: Supports once-daily dosing with sustained therapeutic effect. |
| Protein binding | 97% bound to albumin and α1-acid glycoprotein. |
| Volume of Distribution | Vd: 3.5 L/kg (~245 L for 70 kg adult). Indicates extensive tissue distribution. |
| Bioavailability | Oral: 92% (range 88-96%) |
| Onset of Action | Oral: 30-60 minutes; immediate-release formulation. |
| Duration of Action | Duration: 8-12 hours. Clinical notes: Effective for chronic pain management with steady-state achieved in 2-3 days. |
One tablet orally once daily, each tablet containing 1 mg norethindrone acetate and 20 mcg ethinyl estradiol (21 active tablets) followed by 7 ferrous fumarate tablets.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not recommended for use in severe renal impairment (GFR <30 mL/min) due to lack of data. |
| Liver impairment | Contraindicated in patients with hepatic impairment (Child-Pugh Class B or C). No specific dose adjustment for mild impairment; use with caution. |
| Pediatric use | Safety and efficacy not established in postmenarchal patients; dosing follows adult regimen if indicated. |
| Geriatric use | Not indicated for use in postmenopausal women; no specific dose adjustment recommended due to lack of data. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NORQUEST FE (NORQUEST FE).
| Breastfeeding | Not recommended during breastfeeding. Estrogen and progestin may reduce milk production and quality. Small amounts of steroids and iron are excreted in breast milk; M/P ratio not established for combined hormonal contraceptives. No specific data for NORQUEST FE; avoid use. |
| Teratogenic Risk | Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: estrogen exposure associated with congenital anomalies including cardiovascular and neural tube defects. Second/third trimesters: linked to vaginal adenosis and cervical dysplasia in female offspring, potential for genitourinary abnormalities. Use of iron and calcium components generally safe, but hormonal components (estrogen/norethindrone) pose teratogenic risk. |
■ FDA Black Box Warning
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. Women over 35 years old who smoke should not use this product.
| Serious Effects |
History of thrombophlebitis or thromboembolic disorders, cerebrovascular or coronary artery disease, known or suspected pregnancy, carcinoma of the breast, estrogen-dependent neoplasia, undiagnosed abnormal genital bleeding, jaundice with prior OCs, liver adenoma or carcinoma, hepatic impairment, and hypersensitivity to any component.
| Precautions | Increased risk of thromboembolic disorders, cardiovascular disease (especially in smokers over 35), hepatic neoplasia, gallbladder disease, hypertension, and glucose intolerance. Use with caution in women with risk factors for these conditions. |
Loading safety data…
| Fetal Monitoring | If accidental exposure during pregnancy, perform ultrasound to assess fetal development. Regular prenatal care including detailed anomaly scan. Monitor for signs of fetal compromise if hormonal exposure occurs. No specific maternal monitoring required beyond standard prenatal care; discontinue drug immediately upon pregnancy confirmation. |
| Fertility Effects | Reversible suppression of ovulation, temporary reduction in fertility while on medication. After discontinuation, return to normal fertility expected within 1-3 months. No permanent negative effects on female fertility; does not impair male fertility. |